Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001900438 | SCV002138501 | uncertain significance | not provided | 2024-09-19 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 1208 of the SLC12A2 protein (p.Leu1208Val). This variant is present in population databases (rs761150347, gnomAD 0.05%). This variant has not been reported in the literature in individuals affected with SLC12A2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1373721). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt SLC12A2 protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002482589 | SCV002782823 | uncertain significance | Kilquist syndrome; Hearing loss, autosomal dominant 78; Delpire-McNeill syndrome | 2022-04-29 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001900438 | SCV005401556 | uncertain significance | not provided | 2024-05-17 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |